Double Rainbow appoints Holly Schachner, MD, as Chief Medical Officer

9 Aug 2021

  Close up of microscope lab equipment

CAMBRIDGE, Mass., August 9, 2021 – Today, DoubleRainbow Biosciences, a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human health, announced the appointment of Holly Schachner, MD, as the company’s Chief Medical Officer (CMO). Dr. Schachner joins from MyoKardia, where she was SVP, Therapeutic Head of Clinical Science leading a new therapeutic area focused on diastolic dysfunction, myocardial inflammation, and ischemia.

As our proprietary technology platforms grant us admission to the world of plant enzymes and molecules without harvesting or degrading environmental resources, we are pleased to have someone of Holly’s caliber and experience join our team,” said Jing-Ke Weng, Ph.D., Co-founder of Double Rainbow.

Her experience comes at a critical time for our organization as we are poised to advance several promising early-stage compounds into clinical development and launch our first bioceutical product.
Jing-Ke Weng, Ph.D., Co-founder of Double Rainbow

Prior to joining MyoKardia, Holly was Chief Medical Officer (CMO) Specialty Medicine at Allergan, where she led the transformation to a matrixed medical organization, and developed innovative and global approaches to education and clinical trials. Throughout her career, she has also held leadership roles as North America Medical Head for the Diabetes Cardiovascular (DCV) Business Unit at Sanofi, while serving simultaneously as U.S. Medical Chair, meeting with stakeholders on Capitol Hill to gather insights on patient and healthcare system needs. Earlier in her career, Holly held medical leadership positions at Bayer Diabetes Care, Pfizer, Inc., and Columbia University.

Holly joins an experienced executive team that includes: Chief Business Officer Jamie Jones, Vice President of Global Business Cavan Farley, and Chief of Staff and Senior Director of Business Development Kevin O’Driscoll, who each bring more than 20 years of leadership experience at global, research-based biophar­ma­ceu­tical companies to help better position Double Rainbow to deliver on its aspiration of leading the future of sustainable medicine.

About Double Rainbow

Double Rainbow is a sustainable health care company harnessing the power of natural evolution through bioengineering to improve the quality of human health and ensure the sustainability of our planet. By leveraging advances in the areas of genomics, metabolomics, and synthetic biology we are accessing the richness and efficacy of natural chemistry like never before, to bring therapeutics and bioceuticals to the world at scale without harming the environment. Learn more at www.doublerainbowbio.com.

Media Contact:
Grant Smith
Director, Corporate Communications & Strategic Marketing
317 – 518-9807
grant.smith@doublerainbowbio.com

Related News